MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- AUROBINDO PHARMA - WOCKHARDT
AUROBINDO PHARMA vs WOCKHARDT - Comparison Results
AUROBINDO PHARMA 
Change
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
WOCKHARDT
Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More
Current Valuations
| AUROBINDO PHARMA | WOCKHARDT | AUROBINDO PHARMA/ WOCKHARDT |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 15.4 | -18.4 | - | View Chart |
| P/BV | x | 3.1 | 1.3 | 241.4% | View Chart |
| Dividend Yield | % | 0.4 | 0.0 | 13,447.6% |
Financials
 AUROBINDO PHARMA  WOCKHARDT |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AUROBINDO PHARMA Mar-18 |
WOCKHARDT Mar-18 |
AUROBINDO PHARMA/ WOCKHARDT |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 809 | 1,012 | 79.9% | |
| Low | Rs | 504 | 532 | 94.8% | |
| Sales per share (Unadj.) | Rs | 281.1 | 355.9 | 79.0% | |
| Earnings per share (Unadj.) | Rs | 41.4 | -60.3 | -68.6% | |
| Cash flow per share (Unadj.) | Rs | 50.9 | -46.8 | -108.8% | |
| Dividends per share (Unadj.) | Rs | 2.50 | 0.01 | 25,000.0% | |
| Dividend yield (eoy) | % | 0.4 | 0 | 29,388.8% | |
| Book value per share (Unadj.) | Rs | 199.4 | 257.8 | 77.3% | |
| Shares outstanding (eoy) | m | 585.88 | 110.63 | 529.6% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 2.3 | 2.2 | 107.7% | |
| Avg P/E ratio | x | 15.9 | -12.8 | -124.0% | |
| P/CF ratio (eoy) | x | 12.9 | -16.5 | -78.2% | |
| Price / Book Value ratio | x | 3.3 | 3.0 | 110.0% | |
| Dividend payout | % | 6.0 | 0 | -36,439.0% | |
| Avg Mkt Cap | Rs m | 384,630 | 85,379 | 450.5% | |
| No. of employees | `000 | 17.3 | 6.3 | 277.1% | |
| Total wages/salary | Rs m | 21,308 | 9,371 | 227.4% | |
| Avg. sales/employee | Rs Th | 9,500.7 | 6,295.0 | 150.9% | |
| Avg. wages/employee | Rs Th | 1,229.4 | 1,498.3 | 82.1% | |
| Avg. net profit/employee | Rs Th | 1,397.9 | -1,066.3 | -131.1% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 164,666 | 39,369 | 418.3% | |
| Other income | Rs m | 1,020 | 1,202 | 84.8% | |
| Total revenues | Rs m | 165,686 | 40,571 | 408.4% | |
| Gross profit | Rs m | 37,718 | 18 | 206,106.6% | |
| Depreciation | Rs m | 5,580 | 1,495 | 373.1% | |
| Interest | Rs m | 777 | 2,555 | 30.4% | |
| Profit before tax | Rs m | 32,380 | -2,830 | -1,144.3% | |
| Minority Interest | Rs m | 31 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -3,582 | 0.0% | |
| Tax | Rs m | 8,183 | 257 | 3,183.9% | |
| Profit after tax | Rs m | 24,229 | -6,669 | -363.3% | |
| Gross profit margin | % | 22.9 | 0 | 49,276.8% | |
| Effective tax rate | % | 25.3 | -9.1 | -278.2% | |
| Net profit margin | % | 14.7 | -16.9 | -86.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 121,878 | 33,796 | 360.6% | |
| Current liabilities | Rs m | 86,806 | 26,917 | 322.5% | |
| Net working cap to sales | % | 21.3 | 17.5 | 121.9% | |
| Current ratio | x | 1.4 | 1.3 | 111.8% | |
| Inventory Days | Days | 130 | 79 | 163.7% | |
| Debtors Days | Days | 68 | 89 | 76.6% | |
| Net fixed assets | Rs m | 81,037 | 39,664 | 204.3% | |
| Share capital | Rs m | 586 | 553 | 105.9% | |
| "Free" reserves | Rs m | 116,218 | 27,968 | 415.5% | |
| Net worth | Rs m | 116,804 | 28,522 | 409.5% | |
| Long term debt | Rs m | 4,512 | 21,731 | 20.8% | |
| Total assets | Rs m | 211,052 | 81,620 | 258.6% | |
| Interest coverage | x | 42.7 | -0.1 | -39,679.4% | |
| Debt to equity ratio | x | 0 | 0.8 | 5.1% | |
| Sales to assets ratio | x | 0.8 | 0.5 | 161.8% | |
| Return on assets | % | 11.8 | -5.0 | -235.1% | |
| Return on equity | % | 20.7 | -23.4 | -88.7% | |
| Return on capital | % | 27.4 | -7.7 | -356.5% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 80,727 | 9,807 | 823.2% | |
| Fx outflow | Rs m | 34,700 | 1,789 | 1,940.1% | |
| Net fx | Rs m | 46,027 | 8,019 | 574.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 19,548 | 684 | 2,856.3% | |
| From Investments | Rs m | -19,570 | 6,302 | -310.5% | |
| From Financial Activity | Rs m | 8,642 | -7,695 | -112.3% | |
| Net Cashflow | Rs m | 8,922 | -664 | -1,343.7% | |
Share Holding
| Indian Promoters | % | 54.1 | 74.5 | 72.6% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 8.0 | 2.3 | 345.7% | |
| FIIs | % | 27.7 | 7.7 | 359.7% | |
| ADR/GDR | % | 0.0 | 0.1 | - | |
| Free float | % | 10.2 | 15.4 | 66.2% | |
| Shareholders | 69,601 | 67,757 | 102.7% | ||
| Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: SANOFI INDIA TORRENT PHARMA PLETHICO PHARMA CIPLA ABBOTT INDIA
Compare AUROBINDO PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Opens Marginally Lower; IT Stocks Under Pressure(09:30 am)
Asian share markets edged near this year's peak while benchmark US treasury yields, and the dollar dropped after the Federal Reserve signaled possible interest rate cuts later this year.
Related Views on News
WOCKHARDT Plunges by 7%; BSE HEALTHCARE Index Down 0.4% (Market Updates)
Jun 20, 2019 | Updated on Jun 20, 2019WOCKHARDT share price has plunged by 7% and its current market price is Rs 340. The BSE HEALTHCARE is down by 0.4%. The top gainers in the BSE HEALTHCARE Index are ERIS LIFESCIENCES LIMITED (up 2.6%) and APOLLO HOSPITALS (up 2.1%). The top losers is WOCKHARDT (down 6.9%)..
AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)
May 7, 2019 | Updated on May 7, 2019For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)
Jan 29, 2019 | Updated on Jan 29, 2019For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.
More Views on NewsMost Popular
7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)
Jun 13, 2019We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?
The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)
Jun 11, 2019One chart that predicted the NBFC crisis back in 2016.
Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)
Jun 12, 2019This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.
Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)
Jun 10, 2019The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.
Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)
Jun 14, 2019Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.
More|
| |
AUROBINDO PHARMA SHARE PRICE
Jun 20, 2019 11:17 AM
TRACK AUROBINDO PHARMA
- Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AUROBINDO PHARMA
AUROBINDO PHARMA 5-YR ANALYSIS
COMPARE AUROBINDO PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.